RNA m6A modification is a driver and therapeutic target in gastric cancer
Year: 2026
Type: article
Abstract: N6-methyladenosine (m 6 A), the most abundant modification in eukaryotic RNAs, plays a critical role in regulating RNA stability, expression, and translation. Key m 6 A regulators are up- or down-regulated in human gastric cancer tissues, by Helicobacter pylori and transcription factors, and the aberrant expression is associated with poor patient prognosis. Dynamic m 6 A modification, orchestrated by methyltransferases, demethylases, and m 6 A-binding proteins, profoundly impacts gastric cancer tumorigenesis, metastasis, cancer cell stemness, immune evasion, and resistance to chemotherapy, radiotherapy, and immunotherapy. While aberrant m 6 A modifications and the expression levels of its regulatory factors in blood samples are novel biomarkers in gastric cancer patients, therapies targeting m 6 A regulators have emerged as promising approaches for treating the disease. In summary, m 6 A RNA methylation represents a pivotal epitranscriptomic mechanism with significant implications for gastric cancer biology and precision oncology. RNA m 6 A modification plays a critical role in regulating RNA stability/decay, expression, and translation. m 6 A methyltransferases, demethylases and binding proteins are required for gastric cancer tumorigenesis, metastasis, immune evasion, and resistance to anticancer therapies.
Source: Cell Biology and Toxicology
Authors: Qingjuan Chen, Hongzhao Lu, Dezhi Li, Tao Liu
Institutions: Shaanxi University of Technology, Zhejiang University, UNSW Sydney
Language: English
Topic: RNA modifications and cancer
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,190
Award: G2404032720
OpenAlex ID: W7135368462